Follow
Yu (Ray) Zuo, MD, MSCS
Yu (Ray) Zuo, MD, MSCS
Verified email at med.umich.edu
Title
Cited by
Cited by
Year
Targeting potential drivers of COVID-19: Neutrophil extracellular traps
BJ Barnes, JM Adrover, A Baxter-Stoltzfus, A Borczuk, J Cools-Lartigue, ...
Journal of Experimental Medicine 217 (6), 2020
15602020
Neutrophil extracellular traps in COVID-19
Y Zuo, S Yalavarthi, H Shi, K Gockman, M Zuo, JA Madison, W Woodard, ...
JCI Insight 5 (11), 2020
15022020
Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19
Y Zuo, SK Estes, RA Ali, AA Gandhi, S Yalavarthi, H Shi, G Sule, ...
Science translational medicine 12 (570), eabd3876, 2020
6162020
Neutrophil extracellular traps and thrombosis in COVID-19
Y Zuo, M Zuo, S Yalavarthi, K Gockman, JA Madison, H Shi, W Woodard, ...
Journal of Thrombosis and Thrombolysis 51, 446-453, 2021
2882021
Plasma tissue plasminogen activator and plasminogen activator inhibitor-1 in hospitalized COVID-19 patients
Y Zuo, M Warnock, A Harbaugh, S Yalavarthi, K Gockman, M Zuo, ...
Scientific reports 11 (1), 1580, 2021
2262021
Neutrophil calprotectin identifies severe pulmonary disease in COVID-19
H Shi, Y Zuo, S Yalavarthi, K Gockman, M Zuo, JA Madison, C Blair, ...
Journal of Leucocyte Biology 109 (1), 67-72, 2021
1372021
Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primates
N Brunetti-Pierri, GE Stapleton, M Law, J Breinholt, DJ Palmer, Y Zuo, ...
Molecular Therapy 17 (2), 327-333, 2009
1032009
Pseudo-hydrodynamic delivery of helper-dependent adenoviral vectors into non-human primates for liver-directed gene therapy
N Brunetti-Pierri, GE Stapleton, DJ Palmer, Y Zuo, VP Mane, MJ Finegold, ...
Molecular Therapy 15 (4), 732-740, 2007
972007
Endothelial cell–activating antibodies in COVID‐19
H Shi, Y Zuo, S Navaz, A Harbaugh, CK Hoy, AA Gandhi, G Sule, ...
Arthritis & Rheumatology 74 (7), 1132-1138, 2022
872022
Autoantibodies stabilize neutrophil extracellular traps in COVID-19
Y Zuo, S Yalavarthi, SA Navaz, CK Hoy, A Harbaugh, K Gockman, M Zuo, ...
JCI insight 6 (15), 2021
752021
Anti–neutrophil extracellular trap antibodies and impaired neutrophil extracellular trap degradation in antiphospholipid syndrome
Y Zuo, S Yalavarthi, K Gockman, JA Madison, JE Gudjonsson, ...
Arthritis & Rheumatology 72 (12), 2130-2135, 2020
702020
Prothrombotic antiphospholipid antibodies in COVID-19
Y Zuo, SK Estes, RA Ali, AA Gandhi, S Yalavarthi, H Shi, G Sule, ...
MedRxiv, 2020.06. 15.20131607, 2020
502020
Neutrophil extracellular traps in COVID-19. JCI Insight. 2020
Y Zuo, S Yalavarthi, H Shi, K Gockman, M Zuo, JA Madison, C Blair, ...
Article e138999 View in Scopus, 0
46
Pediatric antiphospholipid syndrome
JA Madison, Y Zuo, JS Knight
European Journal of Rheumatology 7 (Suppl 1), S3, 2020
452020
The interplay between neutrophils, complement, and microthrombi in COVID-19
Y Zuo, Y Kanthi, JS Knight, AHJ Kim
Best practice & research Clinical rheumatology 35 (1), 101661, 2021
422021
New (re) purpose for an old drug: purinergic modulation may extinguish the COVID-19 thromboinflammatory firestorm
Y Kanthi, JS Knight, Y Zuo, DJ Pinsky
JCI insight 5 (14), 2020
412020
Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia B
N Brunetti-Pierri, NC Grove, Y Zuo, R Edwards, D Palmer, V Cerullo, ...
Human gene therapy 20 (5), 479-485, 2009
402009
Antiphospholipid syndrome: a clinical perspective
Y Zuo, H Shi, C Li, JS Knight
Chinese Medical Journal 133 (08), 929-940, 2020
392020
Neutrophil extracellular traps in COVID-19. JCI Insight. 2020; 5 (11): e138999
Y Zuo, S Yalavarthi, H Shi, K Gockman, M Zuo, JA Madison, CN Blair, ...
Go to original source, 0
29
Primary thrombosis prophylaxis in persistently antiphospholipid antibody-positive individuals: where do we stand in 2018?
Y Zuo, M Barbhaiya, D Erkan
Current Rheumatology Reports 20, 1-12, 2018
252018
The system can't perform the operation now. Try again later.
Articles 1–20